PHGE News and Press, Chardan Healthcare Acquisition Corp. From 03/06/24

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 5.9% to $3.1999 on volume of 196,096,419 shares Palantir Technologies Inc. Class A (PLTR) rose 9.8% to $26.14 on volume of 179,511,914 shares WiSA Technologies Inc. (WISA) fell 1...

2024-03-06 12:50:02 ET Gainers: Aptorum Group Ltd ( APM ) +736% . BiomX ( PHGE ) +144% . Trxade Health ( MEDS ) +87% . New Horizon Aircraft Ltd ( HOVR ) +69% . Rail Vision Ltd ( RVSN ) +62% . Airship AI Holdings ( AISP ) ...

2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...

2024-03-06 08:09:27 ET DENVER, Colo., Mar 06, 2024 ( 247marketnews.com )- BiomX Inc. (NYSE: PHGE ) stated, this morning, that it agreed to merge with Adaptive Phage Therapeutics, Inc. (“APT”), a privately-held, clinical-stage biotechnology company that’s based i...

2024-03-06 07:57:24 ET BiomX ( NYSE: PHGE ) shares climbed more than 100% in the premarket on Wednesday after the Israel-based company announced a stock-for-stock merger agreement with Adaptive Phage Therapeutics, a U.S.-based privately owned biotech.... Read the full arti...

Acquisition will create phage therapy company with an advanced pipeline with two P hase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis ( “ CF ” ) patients and BX 2 11 for the treatment of diabetic foot...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that its phage c...

2023-12-07 17:17:22 ET More on BiomX BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day BiomX mulls pivotal trial for antibacterial after Phase 1/2 data in cystic fibrosis For further details see: BiomX files for ...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou...

2023-11-29 07:11:39 ET More on BiomX BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day Seeking Alpha’s Quant Rating on BiomX Historical earnings data for BiomX Financial information for BiomX F...